sever
acut
respiratori
syndrom
due
novel
coronaviru
first
pneumonia
case
unknown
etiolog
identifi
wuhan
china
earli
decemb
genom
sequenc
new
pathogen
diagnost
realtim
revers
transcriptas
polymeras
rtpcr
chain
assay
publish
januari
highthroughput
sequenc
bronchialveolar
sampl
patient
reveal
novel
betacoronaviru
current
name
resembl
sever
acut
respiratori
syndrom
coronaviru
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
far
infect
peopl
worldwid
death
diagnos
patient
world
health
organ
declar
infect
public
health
emerg
intern
concern
major
case
report
china
signific
outbreak
take
place
south
korea
japan
europ
iran
recent
usa
human
host
infect
may
asymptomat
may
caus
syndrom
name
rang
common
cold
sever
pneumonia
acut
respiratori
syndrom
need
mechan
ventil
intens
care
unit
icu
retrospect
chines
studi
consecut
patient
admit
median
time
clinic
onset
hospit
admiss
day
patient
admit
icu
met
clinic
criteria
acut
respiratori
distress
syndrom
ard
anoth
retrospect
chines
studi
critic
ill
patient
pneumonia
show
patient
met
ard
criteria
mortal
day
report
casualti
icu
character
variou
profil
multiorgan
failur
deceas
patient
ard
aki
cardiac
injuri
liver
failur
autopt
find
publish
clinic
case
show
featur
resembl
coronavirusrel
infect
sever
acut
respiratori
distress
syndrom
sar
middl
eastern
resporatori
syndrom
mer
includ
bilater
diffus
alveolar
damag
fibromyxoid
exud
desquam
pneumocyt
hyalin
membran
format
find
cardiac
hepat
tissu
may
suggest
contribut
viral
infect
well
highli
contagi
respons
thousand
casualti
spread
mani
countri
combin
effect
high
transmiss
report
high
incid
sever
diseas
symptomat
patient
pose
threat
healthcar
system
involv
outbreak
differ
way
includ
cumul
casualti
increas
need
hospit
icu
bed
caus
work
overload
healthcar
staff
often
forc
hospit
shut
elect
surgic
activ
high
social
econom
cost
dramat
reduct
product
rigor
quarantin
requir
strategi
curtail
diseas
spread
made
econom
pain
disrupt
suppli
chain
stock
market
todat
treatment
show
increas
surviv
decreas
need
ventilatori
support
patient
sever
acut
respiratori
syndrom
due
respond
epidem
treatment
strategi
safe
quickli
pass
regulatori
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
review
use
massiv
scale
low
cost
therefor
screen
exist
treatment
seem
potenti
choic
clinic
set
ga
approv
us
feder
drug
administr
treatment
pulmonari
hypertens
newborn
presenc
hypox
respiratori
failur
howev
ga
advoc
rescu
treatment
adult
hypox
ard
treatment
ino
revers
pulmonari
hypertens
improv
remark
sever
hypoxemia
shorten
length
ventilatori
support
compar
match
control
patient
sarscov
subsequ
invitro
studi
nitric
oxid
donor
eg
snitrosonacetylpenicillamin
greatli
increas
surviv
rate
sarscovinfect
eukaryot
cell
suggest
direct
antivir
effect
coronaviru
respons
sarscov
share
genom
viru
indic
potenti
effect
ino
therapi
patient
due
similar
coronaviru
respons
sar
hypothes
addit
improv
oxygen
sever
case
ino
ga
retain
potent
antivir
activ
respons
design
studi
assess
whether
continu
deliveri
ino
rescu
therapi
may
increas
oxygen
improv
surviv
patient
studi
set
multicent
random
control
parallelarm
clinic
trial
given
absenc
target
therapi
refractori
hypoxemia
high
mortal
associ
propos
protocol
interest
center
patient
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
exclus
criteria
patient
intub
hour
initi
treatment
ga
physician
contrari
involv
particip
trial
patient
best
interest
condit
allow
protocol
follow
safe
pregnanc
patient
enrol
clinic
intervent
trial
investig
potenti
target
therapi
exclud
particip
trial
patient
treatment
arm
receiv
ino
ppm
first
hour
enrol
reduc
ppm
sever
hypoxemia
resolv
wean
start
patient
improv
level
oxygen
mmhg
hour
consecut
sinc
abrupt
discontinu
ino
sometim
result
rebound
pulmonari
hypertens
possibl
oxygen
impair
acut
right
heart
failur
gradual
discontinu
perform
physician
follow
institut
wean
protocol
absenc
institut
protocol
ino
reduc
everi
hour
stepwis
fashion
start
ppm
ppm
case
hypoxemia
acut
hypotens
systol
blood
pressur
mmhg
wean
ino
increas
prior
higher
concentr
safeti
react
oxygen
form
may
caus
airway
inflamm
damag
lung
tissu
moreov
oxid
ferrou
hb
form
methb
unabl
transport
releas
oxygen
tissu
bind
hb
rapidli
revers
reaction
halflif
min
discontinu
side
effect
advers
event
relat
ino
deliveri
well
report
literatur
base
present
literatur
food
drug
administr
report
risk
breath
ino
ppm
hour
minim
methb
level
deliveri
level
care
monitor
improv
safeti
present
trial
ino
administ
monitor
train
clinician
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
monitor
maintain
level
ppm
methb
continu
monitor
noninvas
cooximetri
methb
level
exceed
circul
hb
concentr
deliv
halv
close
monitor
reduct
occur
methb
level
persist
ino
progress
halv
reduct
occur
blind
studi
blind
patient
outcom
assessor
data
analyst
studi
personnel
deliv
ga
monitor
patient
methemoglobin
level
blind
outcom
primari
outcom
improv
arteri
oxygen
hour
enrol
two
group
patient
die
initi
ga
patient
enter
trial
patient
die
first
hour
treatment
last
avail
blood
ga
analysi
use
level
oxygen
calcul
ratio
patient
follow
day
enrol
secondari
outcom
includ
time
reach
normoxia
defin
least
hour
first
day
enrol
patient
die
day
patient
consid
never
recov
proport
free
patient
ie
normoxiem
patient
first
day
enrol
patient
die
day
patient
consid
never
recov
surviv
day
day
enrol
follow
data
collect
assess
exploratori
outcom
daili
oxygen
two
group
day
need
new
renal
replac
therapi
first
day
mechan
support
circul
ie
ecmo
intraaort
balloon
pump
vad
first
day
day
free
vasopressor
first
day
ventilatorfre
day
day
time
rtpcr
neg
upper
respiratori
tract
specimen
assess
within
first
day
icufre
day
day
sampl
size
hypothes
ga
therapi
lead
improv
oxygen
due
amelior
ventil
perfus
match
patient
affect
differ
ratio
two
group
hour
enrol
consid
clinic
relev
avail
data
oxygen
sarscov
sar
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
hypothes
ino
ga
may
increas
ratio
least
treatment
group
assum
alpha
beta
power
calcul
twosampl
mean
test
satterthwait
test
assum
unequ
varianc
need
patient
dropout
icu
discharg
foreseen
sampl
size
therebi
increas
patient
estim
sampl
size
calcul
use
stata
softwar
recruit
patient
admit
recruit
icu
intub
hypoxemia
screen
elig
patient
exclud
reason
note
screen
log
obtain
inform
consent
detail
studi
present
patient
healthcar
proxi
copi
consent
form
given
patient
healthcar
proxi
prior
initi
studi
procedur
proxi
written
consent
obtain
clinician
random
sequenc
creat
independ
statistician
use
stata
predetermin
block
random
method
fix
block
size
use
ensur
equal
distribut
particip
treatment
arm
upload
studytrax
data
collect
method
clinic
inform
includ
medic
histori
laboratori
exam
obtain
medic
chart
collect
studi
variabl
manag
outcom
assessor
use
dedic
patient
file
studytrax
data
manag
outcom
assessor
treatment
provid
princip
investig
obtain
uniqu
usernam
password
transfer
data
studytrax
page
dedic
studi
statist
method
data
analysi
base
intentiontotreat
principl
patient
die
first
hour
treatment
last
avail
blood
ga
analysi
use
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
assess
primari
outcom
propos
trial
anticip
particip
miss
primari
evalu
demograph
clinic
characterist
present
number
percentag
mean
sd
median
interquartil
rang
iqr
comparison
group
made
use
test
fisher
exact
test
categor
variabl
ttest
wilcoxon
ranksum
test
continu
variabl
appropri
effect
size
describ
probabl
favor
outcom
probabilist
index
ci
calcul
primari
endpoint
compar
use
ttest
mannwhitney
u
appropri
time
reach
normoxia
compar
within
two
group
ttest
mannwhitney
u
test
appropri
exclud
confirm
expect
benefit
oxygen
may
evid
first
day
treatment
decreas
consid
proport
free
patient
day
compar
two
group
term
treatment
success
logrank
test
surviv
curv
gener
via
kaplanmei
method
compar
logrank
test
rate
organ
dysfunct
compar
use
fisher
exact
test
ventilatorfre
day
icufre
day
day
free
vasopressor
time
neg
rtpcr
compar
use
ttest
mannwhitney
u
test
appropri
fisher
exact
test
use
estim
treatment
differ
incid
specifi
advers
event
adjust
made
multipl
hypothesi
evalu
safeti
endpoint
analys
alpha
threshold
consid
signific
adjust
addit
influent
factor
involv
random
process
age
ard
sever
coadministr
experiment
treatment
perform
multivari
logist
regess
analysi
primari
outcom
data
qualiti
safeti
monitor
site
pi
studi
medic
coordin
center
mcc
data
safeti
monitor
board
dsmb
site
pi
continu
monitor
data
qualiti
accord
data
qualiti
measur
addit
recruit
rate
deviat
inclusionexclus
criteria
protocol
confidenti
data
databas
monitor
dsmb
draw
person
expertis
area
constitut
interim
analysi
perform
plan
enrol
dsmb
evalu
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
surviv
rate
two
group
dsmb
determin
whether
studi
continu
termin
dsmb
play
valuabl
role
advis
studi
leadership
relev
advanc
diagnosi
treatment
patient
number
therapeut
diagnost
test
advanc
may
possibl
occur
cours
trial
protocol
modif
warrant
close
consult
among
dsmb
studi
leadership
requir
separ
dsmb
charter
outlin
detail
oper
guidelin
committe
protocol
evalu
data
develop
prior
start
patient
random
agre
upon
initi
meet
dsmb
harm
organ
failur
prolong
hospit
mortal
record
part
studi
defin
outcom
advers
event
monitor
site
pi
research
specialist
real
time
start
random
hospit
discharg
death
report
advers
event
includ
hemodynam
chang
deterior
oxygen
relat
inhal
requir
adjust
concentr
seriou
advers
event
studi
defin
report
advers
event
fatal
lifethreaten
perman
disabl
advers
event
indic
data
form
studi
specif
advers
event
report
form
seriou
advers
event
report
site
irb
within
hour
research
team
learn
event
follow
detail
written
report
local
irb
follow
inform
advers
event
collect
onset
resolut
event
assess
sever
intens
event
assess
relationship
event
intervent
action
taken
event
site
inform
principl
investig
cl
lb
coordin
center
xije
hospit
massachusett
gener
hospit
relat
advers
event
directli
caus
inhal
nonseri
within
day
discoveri
fatal
lifethreaten
perman
disabl
regardless
related
event
due
inhal
must
report
coordin
center
within
hour
discoveri
principl
investig
report
event
dsmb
coordin
center
irb
patient
public
involv
particip
inform
recruit
arm
studi
result
year
random
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
ethic
dissemin
studi
conduct
follow
good
clinic
practic
intern
confer
harmon
good
clinic
practic
ichgcp
well
local
nation
regul
result
studi
publish
scientif
journal
present
scientif
meet
person
inform
enrol
particip
collect
studytrax
platform
dissemin
polici
result
publish
access
healthcar
profession
public
